|
QTRT2 antibody detects Queuine tRNA-ribosyltransferase subunit 2, encoded by the QTRT2 gene on chromosome 6p25.1. QTRT2 antibody is widely used in RNA modification, translation, and metabolism research. QTRT2 partners with QTRT1 to form the heterodimeric
|
Buy from Supplier |
|
Santa Cruz Biotechnology
queuine hydrochloride ![]() Queuine Hydrochloride, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/queuine/pmc12465891-121-0-2?v=Santa+Cruz+Biotechnology Average 93 stars, based on 1 article reviews
queuine hydrochloride - by Bioz Stars,
2026-08
93/100 stars
|
Buy from Supplier |
|
Marburg GmbH
queuine ![]() Queuine, supplied by Marburg GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/queuine/10__1128_slash_mbio__03549___20-359-5-14?v=Marburg+GmbH Average 90 stars, based on 1 article reviews
queuine - by Bioz Stars,
2026-08
90/100 stars
|
Buy from Supplier |
|
Holobiome Inc
queuine ![]() Queuine, supplied by Holobiome Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/queuine/pm32381701-116-12-9?v=Holobiome+Inc Average 90 stars, based on 1 article reviews
queuine - by Bioz Stars,
2026-08
90/100 stars
|
Buy from Supplier |
|
QTRT1 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 428 amino acids (1-403 a.a) and having a molecular mass of 46.7kDa. QTRT1 is fused to a 25 amino acid His-tag at
|
Buy from Supplier |
|
Queuine TRNA-Ribosyltransferase Domain Containing 1, Human Recombinant; 10 ug
|
Buy from Supplier |
|
QTRTD1, 1-415aa Human, His tag, E.coliQTRTD1 interacts with QTRT1 to form an active queuine tRNA-ribosyltransferase. This enzyme exchanges queuine for the guanine at the wobble position of tRNAs with GUN anticodons (tRNA-Asp, -Asn, -His and
|
Buy from Supplier |
|
Queuine TRNA-Ribosyltransferase 1, Human Recombinant; 5 ug
|
Buy from Supplier |
Image Search Results
Journal: BMC Biotechnology
Article Title: In silico screening and in vitro biological evaluation reveal Queuine as a promising MAP4K4 inhibitor for treating pancreatic cancer
doi: 10.1186/s12896-025-01033-w
Figure Lengend Snippet: Interaction analysis of the control drug Gemcitabine and the proposed nutraceutical therapeutics Queuine and Thiamine with the MAP4K4 binding site. ( A ) 3D binding pose of Gemcitabine (left) and 2D representation (right) of Gemcitabine docked in the MAP4K4 binding site. ( B ) 3D and 2D binding pose of Queuine ( C ) 3D and 2D binding pose of Thiamine. Coloring schemes: hydrogen bonding (purple arrows), pi-pi stacking (green line), and pi-cation interactions (red line)
Article Snippet:
Techniques: Control, Binding Assay
Journal: BMC Biotechnology
Article Title: In silico screening and in vitro biological evaluation reveal Queuine as a promising MAP4K4 inhibitor for treating pancreatic cancer
doi: 10.1186/s12896-025-01033-w
Figure Lengend Snippet: Protein-ligand complex root mean square deviation (RMSD) ( A ) and root mean square fluctuation (RMSF) ( B ) plots for the apo, Gemcitabine, Queuine, and Thiamine bound forms of the MAP4K4 protein
Article Snippet:
Techniques:
Journal: BMC Biotechnology
Article Title: In silico screening and in vitro biological evaluation reveal Queuine as a promising MAP4K4 inhibitor for treating pancreatic cancer
doi: 10.1186/s12896-025-01033-w
Figure Lengend Snippet: Schematic showing the durability of ligand-protein interactions during MD simulations. ( A ) Queuine-protein contacts prolonged for more than 50% of the simulation time. ( B ) Thiamine has shorter-lived less prolonged contacts
Article Snippet:
Techniques:
Journal: BMC Biotechnology
Article Title: In silico screening and in vitro biological evaluation reveal Queuine as a promising MAP4K4 inhibitor for treating pancreatic cancer
doi: 10.1186/s12896-025-01033-w
Figure Lengend Snippet: Final snapshots at the end of the 100 ns MD simulations for Queuine ( A ), Thiamine ( B ), and Gemcitabine ( C )
Article Snippet:
Techniques:
Journal: BMC Biotechnology
Article Title: In silico screening and in vitro biological evaluation reveal Queuine as a promising MAP4K4 inhibitor for treating pancreatic cancer
doi: 10.1186/s12896-025-01033-w
Figure Lengend Snippet: Viability of Panc-1 cells compared with that of the control group after exposure to different concentrations of Queuine ( A ), Thiamine ( B ) and Gemcitabine ( C ) for 48 h. The results represent the average ± SEM of the results from each experiment, which were repeated three times at different times with the same concentration ranges. The statistical significance was evaluated according to a p-value of < 0.05.Compared with the control, *p< \0.05, **p< \0.01
Article Snippet:
Techniques: Control, Concentration Assay
Journal: BMC Biotechnology
Article Title: In silico screening and in vitro biological evaluation reveal Queuine as a promising MAP4K4 inhibitor for treating pancreatic cancer
doi: 10.1186/s12896-025-01033-w
Figure Lengend Snippet: Effects of different concentrations of Queuine and Gemcitabine on MAP4K4 activity. Absorbance values on the y-axis represent the enzyme amount measured using an ELISA kit, with different concentrations of Queuine ( A ) and Gemsitabine ( B ) indicated on the x-axis. The differences between the bar pairs marked with * ( p < 0.05) and *** ( p < 0.001) are significant
Article Snippet:
Techniques: Activity Assay, Enzyme-linked Immunosorbent Assay
Journal: BMC Biotechnology
Article Title: In silico screening and in vitro biological evaluation reveal Queuine as a promising MAP4K4 inhibitor for treating pancreatic cancer
doi: 10.1186/s12896-025-01033-w
Figure Lengend Snippet: Viability of Panc-1 cells compared with that of the control group after exposure to combined treatment of Queuine (QUE) and Gemcitabine (GEM) for 48 h. A ) Queuine (0.25 µM) with gemcitabine combination, B ) Queuine (1.25 µM) with gemcitabine combination
Article Snippet:
Techniques: Control
Journal: BMC Biotechnology
Article Title: In silico screening and in vitro biological evaluation reveal Queuine as a promising MAP4K4 inhibitor for treating pancreatic cancer
doi: 10.1186/s12896-025-01033-w
Figure Lengend Snippet: Synergetic effects of Queuine and Gemcitabine on MAP4K4 activity. Absorbance values represent the enzyme amount measured using an ELISA kit. The difference between bar pairs marked with *** are significant at p < 0.001
Article Snippet:
Techniques: Activity Assay, Enzyme-linked Immunosorbent Assay